title: High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial.
abstract: BACKGROUND
  People with multiple sclerosis have high risk of osteoporosis and fractures. A poor vitamin D status is a risk factor for MS, and vitamin D supplementation has been recommended both to prevent MS progression and to maintain bone health.
  
  
  METHODS
  We assessed the effect of 20,000 IU vitamin D3weekly compared to placebo on biochemical markers of bone metabolism in 68 persons with relapsing remitting multiple sclerosis.
  
  
  RESULTS
  Serum levels of 25-hydroxyvitamin D more than doubled in the vitamin D group, and parathyroid hormone decreased in the vitamin D group compared to the placebo group at week 48 and week 96. There was however no effect on bone formation as measured by procollagen type I N propeptide (PINP), or on bone resorption as measured by C-terminal cross-linking telopeptide of type I collagen (CTX1). Neither PINP nor CTX1 predicted bone loss from baseline to week 96.
  
  
  CONCLUSIONS
  These findings corroborate the previously reported lack of effect of weekly high dose vitamin D supplementation on bone mass density in the same patients, and suggest that such vitamin D supplementation does not prevent bone loss in persons with MS who are not vitamin D deficient.
  
  
  BACKGROUND
  The trial was registered at ClinicalTrials.gov on April 4 2008, registration number NCT00785473 .
authors.affiliation: Department of Neurology, Akershus University Hospital, Lørenskog, Norway. Trygve.holmoy@medisin.uio.no.|Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Trygve.holmoy@medisin.uio.no.
authors.forename: Trygve
authors.identifier: http://orcid.org/0000-0002-2529-5664
authors.initials: T
authors.lastname: Holmøy
authors.affiliation: Institute of Clinical Medicine, University of Oslo, Oslo, Norway.|Helse Øst Health Services and Research Centre, Akershus University Hospital, Lørenskog, Norway.
authors.forename: Jonas Christoffer
authors.initials: JC
authors.lastname: Lindstrøm
authors.affiliation: Institute of Clinical Medicine, University of Oslo, Oslo, Norway.|Department of Endocrinology, Oslo University Hospital, Oslo, Norway.
authors.forename: Erik Fink
authors.initials: EF
authors.lastname: Eriksen
authors.affiliation: Department of Neurology, University Hospital of North Norway, Tromsø, Norway.|Department of Clinical Medicine, University of Tromsø, Tromsø, Norway.
authors.forename: Linn Hofsøy
authors.initials: LH
authors.lastname: Steffensen
authors.affiliation: Department of Neurology, University Hospital of North Norway, Tromsø, Norway.
authors.forename: Margitta T
authors.initials: MT
authors.lastname: Kampman
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002762:Cholecalciferol / Q000008:administration & dosage / Q000494:pharmacology*; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood / Q000188:drug therapy*; D010024:Osteoporosis / Q000097:blood / Q000517:prevention & control*; D016896:Treatment Outcome; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood; D055815:Young Adult
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D014807:Vitamin D; D002762:Cholecalciferol; C104450:25-hydroxyvitamin D
keywords: Multiple sclerosis; osteoporosis; randomized controlled trial; vitamin D